Business Wire

Thales Expands Technology Partner Ecosystem to Accelerate Enterprises’ Cloud and Digital Transformation Initiatives

12.8.2020 11:00:00 EEST | Business Wire | Press release

Share

Enterprises can now reduce cyber risk and secure their digital transformation initiatives in new markets including Blockchain, Cloud, DevOps, IoT and Code Signing as Thales unveils an expansion of its data protection ecosystem to more than 300 technology partners.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200812005038/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Photo : Thales)

Through these expanded technology integrations, which now include more than 500 IT products and services, Thales is enabling more organisations to integrate its data encryption, hardware security modules, key management and access management technologies with their existing IT infrastructure and cloud services to protect applications, data and identities. This will empower organisations to implement centralised data protection and access management controls for the whole customer journey.

“The use of the cloud and digital transformation is now the cornerstone of any modern company,” said Sebastien Cano, Senior Vice President for Cloud Protection and Licensing Activities at Thales. “Vitally though, those that are truly leading the way are doing so by integrating security by design into their processes from the start. By integrating our data protection products and services with hundreds of technology partners, we can ensure customers and their sensitive data are protected throughout their entire transformation journey and remain at the forefront of their industries.”

Protecting Blockchain

Thales is collaborating with leading companies that are driving the adoption of Blockchain technology by integrating its Luna Network Hardware Security Modules (HSM) as the root of trust to secure blockchain-based transactions. Recently, Thales integrated its Luna Network HSM with CLS Group – a dedicated crypto processor that is specifically designed for the protection of the crypto key lifecycle – and Hyperledger – a multi-project open source collaborative effort hosted by The Linux Foundation, created to advance cross-industry blockchain technologies.

Enabling Secure Cloud Transformation

Today, organisations on average use 29 cloud services for their collaboration, computing, customer relationship management and storage needs. Thales is helping companies secure the move to the cloud with cloud key management and access management solutions that integrate with the most widely used cloud platforms and services including AWS, Azure, Box, Office365 and Slack.

Thales’s SafeNet Trusted Access enables organisations to modernise their IT and Identity and Access Management (IAM) schemes, as part of their cloud transformation initiatives. For example, integrations with IGA vendors such as SailPoint enable secure identity governance and identity management workflows; Security for privileged users is achieved by securing PAM solutions such as BeyondTrust, at the access point; and continuous authentication and access control is enabled by working with CipherCloud’s CASB solution.

Securing Hybrid IT Environments

While organisations are rapidly adopting cloud services and moving infrastructure to the cloud, the majority are maintaining hybrid IT environments. One of the key challenges they face in doing so is bridging between modern and cloud IAM schemes. To this end, SafeNet Trusted Access’s integration with F5 BIG IP enables enterprises to implement smart SSO for cloud services while securing on premises legacy applications.

“Data and applications are fast becoming the lifeblood of any organisation, no matter the industry,” said John Morgan, VP & GM Security at F5. “For any customer to truly take advantage of this digital transformation, applications and their underlying data must be secure. By joining the Thales partner ecosystem, we are continuing our long history of collaboration to help customers achieve positive business outcomes through secure digital transformation.”

Enabling Trust for DevOps

Digital certificates play an integral role in DevOps workflows, securing authentication across users, devices and applications. The secure identities and certificates establish trust within enterprise infrastructure, pipeline, code and containers. Thales has expanded its DevOps technology partners to include Red Hat, HashiCorp, Kubernetes, VMWare Tanzu, Docker and Google for secure DevOps to enable customers to realise the benefits of automation, scale, & cloud native applications and digital transformation.

Securing the Identities and Data in IoT

In order to secure, manage and authenticate the billions of identities that will be created with the Internet of Things, Thales has recently expanded integrations for its HSMs, Data Encryption and Key Management solutions with leading providers of IoT security solutions such as Cisco, Microsoft, DigiCert, Sectigo, GlobalSign, KeyFactor and Venafi to help organisations secure the billions of identities that will be created over the next few years.

Code Signing becomes an essential service for businesses

Code signing has emerged as an essential ingredient to doing business for virtually any organisation that distributes code to customers and partners. Code signing verifies who the publisher of a specific set of code is and attests that it has not been modified since it was signed. Certificates delivered along with software that has been signed are a key way for users to determine whether software originates from a legitimate source before installing. Today, many software marketplaces, including mobile app stores, require code to be compliant with specific digital signing requirements.

One of those mandates is for applicants to generate and store their private key using a FIPS 140-2 Level 2 certified hardware solution. This can be a Hardware Security Module (HSM) that protects the identity, whether it is the server, virtualization server or the user. Thales' HSMs take the security one step further by storing the signing material in a hardware device, thus ensuring authenticity and integrity of a code file. Thales code signing partners include Adobe, DigiCert, Garantir GlobalSign, Keyfactor, Microsoft and Venafi.

About Thales

Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019 (on a pro forma basis including Gemalto over 12 months).

Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments.

PLEASE VISIT
Thales Group
Market page

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PRESS

Thales, Media Relations
Constance Arnoux
+33 (0)6 44 12 16 35
constance.arnoux@thalesgroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye